NIH releases strategic plan to address tuberculosis research

Scanning electron micrograph of Mycobacterium tuberculosis, the bacteria that cause tuberculosis. NIAID

What

Tuberculosis (TB) is the leading infectious cause of death worldwide, killing roughly 1.6 million people in 2017. In the past 200 years, TB claimed the lives of more than 1 billion people — more deaths than from malaria, influenza, smallpox, HIV/AIDS, cholera and plague combined.

Recently, the global health community has strengthened its efforts and resolve to tackle this ancient disease. Writing in the Journal of the American Medical Association, Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, details the institute’s new strategic plan for building on these current efforts by furthering the understanding of TB and developing and applying cutting-edge tools to fight the disease.

The NIAID Strategic Plan for Tuberculosis Research prioritizes expanding fundamental knowledge of TB by using modern tools, such as state-of-the-art imaging and systems biology methods, to better understand how TB infection remains latent in some individuals and then progresses to active disease, as well as the host and microbial factors that affect TB disease, transmission, and epidemiology. The plan is being released to coincide with the United Nations General Assembly High-Level Meeting on Ending TB on September 26.

In 2017, an estimated 3.6 million of 10 million new TB cases went undiagnosed or unreported, according to the World Health Organization. To address this gap, NIAID is calling for improved TB diagnostics, specifically, the development of tests that can be performed rapidly, accurately, inexpensively, and at the point-of-care for different forms of TB as well as for all populations, including children and people living with HIV. NIAID will support research on emerging technologies, such as nanotechnology, and identify host and microbial biomarkers that can be integrated into platforms that diagnose infection, indicate the risk of disease progression, or predict disease recurrence, Fauci writes.

Safe, broadly effective vaccines and short-course drug regimens to prevent TB infection, latent disease or the progression to active TB disease are also badly needed, according to Fauci. To that end, NIAID will support advanced technologies, assays, and animal models to facilitate the design of novel TB vaccines and to identify markers of protective immunity. Additionally, the institute will assess preventive drug regimens that interrupt transmission.

People living with TB currently must take lengthy and sometimes toxic treatment regimens for multidrug resistant and extensively drug-resistant TB. For people co-infected with TB and HIV, drug-drug interactions are particularly problematic. To address these challenges, NIAID will focus efforts on developing effective, shorter-duration therapeutics for latent and active drug-sensitive and drug-resistant TB, including host-directed therapies. Existing drugs approved for other indications will be assessed for repurposing to identify the most effective treatments with the shortest duration, according to Fauci. Further, research to understand the mechanisms of action and adverse effects of therapeutics will be conducted to prevent or reduce drug toxicity.

NIAID also will expand research resources and infrastructure, so that scientists can gain access to appropriate facilities and databases for sharing large, diverse data sets. Additionally, the institute will foster opportunities for early-stage investigators, support improved animal models, and facilitate development of assays, reagents and other tools.

Ending the TB epidemic will require an accelerated, collaborative global effort from diverse scientific disciplines, Fauci writes. NIAID will implement and lead a reinvigorated research program to build the tools for transformative improvements in TB diagnosis, prevention and treatment that are needed to end TB.

Article

AS Fauci. Addressing the Tuberculosis Epidemic: 21st Century Research for an Ancient Disease Journal of the American Medical Association DOI: 10.1001/jama.2018.12852.

The NIAID Strategic Plan for Tuberculosis Research is available online at: https://www.niaid.nih.gov/sites/default/files/TBStrategicPlan2018.pdf.

Who

NIAID Director Anthony S. Fauci, M.D., is available to discuss the article and the NIAID Strategic Plan for Tuberculosis Research.

Contact

To schedule interviews, please contact the NIAID News Office at (301) 402-1663 or via e-mail at niaidnews@niaid.nih.gov(link sends e-mail).

NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

###